Compare AbCellera Biologics Inc (ABCL) vs First Citizens BancShares Inc (FCNCA) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs First Citizens BancShares Inc — how do they compare? AbCellera Biologics Inc trades at $7.14 (market cap $2.35B), while First Citizens BancShares Inc trades at $2,045.06 (market cap $23.94B). The key difference: First Citizens BancShares Inc is far larger — about 10.2× AbCellera Biologics Inc's market cap, and First Citizens BancShares Inc pays a 0.4% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | FCNCA | |
|---|---|---|
Market Cap | $2.35B | $23.94B |
Sector | Health | Sector/Thematic |
52-Week High | $8.12 | $2.20K |
52-Week Low | $2.78 | $1.64K |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 0.4% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
First Citizens BancShares (FCNCA) trades at $2,117.35, up 1.65% on the day, with a bullish technical signal from moving averages. The stock shows strong fundamental health with a P/E of 12.21 and net income margin of 24.35%, supported by consecutive earnings beats including Q1 2026 EPS of $44.86 versus $39.56 expected. Recent corporate developments include the planned rebranding of Silicon Valley Bank and expansion of commercial banking capabilities.
The outlook remains positive given earnings momentum and analyst consensus price target of $2,320, though risks include margin pressure and credit exposure from the SVB integration. Upside potential hinges on continued execution amid a competitive banking landscape.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About First Citizens BancShares Inc
First Citizens BancShares is a major US regional bank providing diverse financial services. It recently expanded significantly by acquiring the assets and liabilities of Silicon Valley Bank.
Read more on FCNCA →
